Tue. 7 May 2024, 4:24pm ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.69 by 14.49 percent. The company reported quarterly sales of $195.879 million which missed the analyst consensus estimate of $199.777 million by 1.95 percent. This is a 20.81 percent increase over sales of $162.143 million the same period last year.